M Kuwana1, Y Okazaki, Y Ikeda. 1. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. kuwanam@sc.itc.keio.ac.jp
Abstract
BACKGROUND: Immune thrombocytopenic purpura (ITP) is an autoimmune disease primarily caused by IgG anti-platelet autoantibodies. Activation of autoreactive CD4(+) T cells upon recognition of cryptic GPIIb/IIIa peptides presented by antigen-presenting cells (APCs) is a critical step for triggering and maintaining the pathogenic anti-platelet autoantibody response. OBJECTIVES: We investigated which APCs carry the cryptic peptides of GPIIb/IIIa that activate autoreactive CD4(+) T cells in ITP patients. METHODS: GPIIb/IIIa-reactive T-cell lines generated from ITP patients were cultured with autologous freshly isolated splenic macrophages, B cells or dendritic cells. To further investigate how the macrophages presented the antigenic GPIIb/IIIa peptides, we prepared macrophages from the peripheral blood monocytes of the same patients during remission. RESULTS: Macrophages induced the proliferation of GPIIb/IIIa-reactive T-cell lines without an exogenous antigen, but B cells and dendritic cells required GPIIb/IIIa peptides to stimulate the T cells. Macrophages derived from peripheral blood during remission required an exogenous antigen to induce the GPIIb/IIIa-reactive T-cell line response, but could elicit a response without added antigen if they were preincubated with platelets from ITP patients with platelet-associated anti-GPIIb/IIIa antibodies or healthy platelets pretreated with ITP platelet eluates. The T-cell response was inhibited by anti-FcgammaRI antibody. Finally, cultured macrophages that captured opsonized platelets promoted anti-GPIIb/IIIa antibody production in mixed cultures of autologous GPIIb/IIIa-reactive T-cell lines and B cells. CONCLUSIONS: Splenic macrophages that take up opsonized platelets via FcgammaRI are major APCs for cryptic GPIIb/IIIa peptides, and are central to the maintenance of anti-platelet autoantibody production in ITP patients.
BACKGROUND: Immune thrombocytopenic purpura (ITP) is an autoimmune disease primarily caused by IgG anti-platelet autoantibodies. Activation of autoreactive CD4(+) T cells upon recognition of cryptic GPIIb/IIIa peptides presented by antigen-presenting cells (APCs) is a critical step for triggering and maintaining the pathogenic anti-platelet autoantibody response. OBJECTIVES: We investigated which APCs carry the cryptic peptides of GPIIb/IIIa that activate autoreactive CD4(+) T cells in ITP patients. METHODS:GPIIb/IIIa-reactive T-cell lines generated from ITP patients were cultured with autologous freshly isolated splenic macrophages, B cells or dendritic cells. To further investigate how the macrophages presented the antigenic GPIIb/IIIa peptides, we prepared macrophages from the peripheral blood monocytes of the same patients during remission. RESULTS: Macrophages induced the proliferation of GPIIb/IIIa-reactive T-cell lines without an exogenous antigen, but B cells and dendritic cells required GPIIb/IIIa peptides to stimulate the T cells. Macrophages derived from peripheral blood during remission required an exogenous antigen to induce the GPIIb/IIIa-reactive T-cell line response, but could elicit a response without added antigen if they were preincubated with platelets from ITP patients with platelet-associated anti-GPIIb/IIIa antibodies or healthy platelets pretreated with ITP platelet eluates. The T-cell response was inhibited by anti-FcgammaRI antibody. Finally, cultured macrophages that captured opsonized platelets promoted anti-GPIIb/IIIa antibody production in mixed cultures of autologous GPIIb/IIIa-reactive T-cell lines and B cells. CONCLUSIONS: Splenic macrophages that take up opsonized platelets via FcgammaRI are major APCs for cryptic GPIIb/IIIa peptides, and are central to the maintenance of anti-platelet autoantibody production in ITP patients.
Authors: S Audia; K Santegoets; A G Laarhoven; G Vidarsson; O Facy; P Ortega-Deballon; M Samson; N Janikashvili; P Saas; B Bonnotte; T R Radstake Journal: Clin Exp Immunol Date: 2017-02-28 Impact factor: 4.330
Authors: Lisa M Sedger; Arna Katewa; Ann K Pettersen; Sarah R Osvath; Geoff C Farrell; Graeme J Stewart; Linda J Bendall; Stephen I Alexander Journal: Blood Date: 2010-02-25 Impact factor: 22.113
Authors: Sylvain Audia; Maxime Samson; Julien Guy; Nona Janikashvili; Jennifer Fraszczak; Malika Trad; Marion Ciudad; Vanessa Leguy; Sabine Berthier; Tony Petrella; Serge Aho-Glélé; Laurent Martin; Marc Maynadié; Bernard Lorcerie; Patrick Rat; Nicolas Cheynel; Emmanuel Katsanis; Nicolas Larmonier; Bernard Bonnotte Journal: Blood Date: 2011-08-29 Impact factor: 22.113
Authors: Matthieu Mahévas; Pauline Patin; François Huetz; Marc Descatoire; Nicolas Cagnard; Christine Bole-Feysot; Simon Le Gallou; Mehdi Khellaf; Olivier Fain; David Boutboul; Lionel Galicier; Mikael Ebbo; Olivier Lambotte; Mohamed Hamidou; Philippe Bierling; Bertrand Godeau; Marc Michel; Jean-Claude Weill; Claude-Agnès Reynaud Journal: J Clin Invest Date: 2012-12-17 Impact factor: 14.808